https://charts.traderzeitung.de/phases/US02043Q1076
string(1467) "{"isin":"US02043Q1076","name":"Alnylam Pharmaceuticals Inc","stock_id_xnas":7873158,"stock_id_xnys":null,"generated_at":"2026-08-22 17:38:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":242.71,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":244,"close_at":"2026-08-20 01:35:00","complete":true,"perf_pct":0.5315}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":229.4,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-5.9836},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":229.06,"close_at":"2026-08-21 15:28:00","complete":true,"perf_pct":-0.1482},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":236.08,"close_at":"2026-08-21 21:59:00","complete":true,"perf_pct":3.0647},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":237.49,"close_at":"2026-08-21 22:01:00","complete":true,"perf_pct":0.5973}]}]}"
Alnylam Pharmaceuticals Aktie News & Nachrichten
Das Biotechunternehmen hat sich auf Medikamente auf Basis der RNA-Interferenz (RNAi) spezialisiert,...
